ARS Pharmaceuticals, Inc. (SPRY)
USD 10.96
(-6.8%)
USD 10.96
(-6.8%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -59.26 Million | -40.07 Million | -17.56 Million | 9.07 Million | -18.89 Million | -16.87 Million |
| Net Income | -54.36 Million | -34.68 Million | -20.24 Million | -1.06 Million | -23.96 Million | -17.57 Million |
| Depreciation & Amortization | 73 Thousand | 319 Thousand | 6000.00 | 6000.00 | 1.54 Million | 1.42 Million |
| Deferred income taxes | 2.77 Million | - | -4000.00 | 1000.00 | - | - |
| Stock-based compensation | 9.23 Million | 5.84 Million | 2.82 Million | 3.54 Million | - | - |
| Change in working capital | -7.33 Million | -12.75 Million | -356 Thousand | 6.46 Million | 3.3 Million | -433 Thousand |
| Other non-cash items | -9.65 Million | 1.19 Million | 207 Thousand | 121 Thousand | -699 Thousand | 2.04 Million |
| Investing Cash Flow | -87.18 Million | -199 Thousand | -55 Thousand | -917 Thousand | -96 Thousand | -449 Thousand |
| Investments in PPE | -175 Thousand | -199 Thousand | -55 Thousand | -917 Thousand | -96 Thousand | -449 Thousand |
| Acquisitions | 87 Million | - | - | - | - | - |
| Investment purchases | -272 Million | - | -65.1 Million | - | - | - |
| Sales/Maturities of investments | 185 Million | - | - | - | - | - |
| Other Investing Activities | -87 Million | - | 65.1 Million | - | - | - |
| Financing Cash Flow | 6.89 Million | 190.73 Million | 53.15 Million | 5.09 Million | 8.61 Million | 19.39 Million |
| Debt repayment | - | -8.68 Million | -1.81 Million | -700 Thousand | -8.59 Million | -852 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 6.89 Million | 570 Thousand | 54.97 Million | 409.2 Million | 19 Thousand | 20.25 Million |
| Other Financing Activities | 6.89 Million | 198.84 Million | 53.15 Million | -403.4 Million | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.77 Million | -10.28 Million | 6.03 Million | 1.79 Million | 4.01 Million | 513 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -4.55 Million | -2.46 Million | -6.39 Million | 4.67 Million | -714 Thousand | -946 Thousand |
| Cash at beginning of period | 210.51 Million | 60.06 Million | 24.52 Million | 10.35 Million | 20.16 Million | 18.08 Million |
| Cash at end of period | 70.97 Million | 210.51 Million | 60.06 Million | 24.52 Million | 9.97 Million | 20.16 Million |
| Capital Expenditure | -175 Thousand | -199 Thousand | -55 Thousand | -917 Thousand | -96 Thousand | -449 Thousand |
| Effect of forex changes on cash | - | - | - | 917 Thousand | 200 Thousand | - |
| Net cash flow / Change in cash | -139.54 Million | 150.45 Million | 35.54 Million | 14.17 Million | -10.18 Million | 2.07 Million |
| Free Cash Flow | -59.44 Million | -40.27 Million | -17.61 Million | 8.15 Million | -18.99 Million | -17.32 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.51 Million | -10.29 Million | -54.36 Million | -7.16 Million | -14.86 Million | -17.37 Million |
| Depreciation & Amortization | 18 Thousand | 11 Thousand | 73 Thousand | 12 Thousand | 21 Thousand | 20 Thousand |
| Deferred income taxes | - | - | 2.77 Million | -11.18 Million | - | - |
| Stock-based compensation | 3.36 Million | 3.31 Million | 9.23 Million | 2.27 Million | 2.6 Million | 2.09 Million |
| Change in working capital | 3.75 Million | 2.23 Million | -7.33 Million | -10.77 Million | 1.03 Million | 335 Thousand |
| Other non-cash items | -1.56 Million | 13 Thousand | -9.65 Million | 9.42 Million | -1.56 Million | -1.75 Million |
| Investing Cash Flow | -12.64 Million | -8.51 Million | -87.18 Million | 26.03 Million | -46.64 Million | 44.97 Million |
| Investments in PPE | -38 Thousand | -83 Thousand | -175 Thousand | 91 Thousand | -43 Thousand | -30 Thousand |
| Acquisitions | - | - | 87 Million | -25.94 Million | 46.6 Million | - |
| Investment purchases | -87.6 Million | -63.43 Million | -272 Million | -34.05 Million | -106.6 Million | - |
| Sales/Maturities of investments | 75 Million | 55 Million | 185 Million | 60 Million | 60 Million | 45 Million |
| Other Investing Activities | -12.6 Million | -8.43 Million | -87 Million | 25.94 Million | -46.6 Million | 45 Million |
| Financing Cash Flow | 545 Thousand | 258 Thousand | 6.89 Million | 1.8 Million | 921 Thousand | 2.85 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 545 Thousand | 258 Thousand | 6.89 Million | 1.8 Million | 921 Thousand | 2.85 Million |
| Other Financing Activities | 545 Thousand | 258 Thousand | 6.89 Million | 1.8 Million | 921 Thousand | 2.85 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 3.06 Million | 1.34 Million | -2.77 Million | -8.88 Million | 1.12 Million | 224 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 692 Thousand | 892 Thousand | -4.55 Million | -1.88 Million | -91 Thousand | 111 Thousand |
| Cash at beginning of period | 56 Million | 70.97 Million | 210.51 Million | 60.53 Million | 119.01 Million | 87.86 Million |
| Cash at end of period | 36.62 Million | 56 Million | 70.97 Million | 70.97 Million | 60.53 Million | 119.01 Million |
| Capital Expenditure | -38 Thousand | -83 Thousand | -175 Thousand | 91 Thousand | -43 Thousand | -30 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -19.38 Million | -14.96 Million | -139.54 Million | 10.43 Million | -58.48 Million | 31.15 Million |
| Free Cash Flow | -7.31 Million | -6.79 Million | -59.44 Million | -17.31 Million | -12.8 Million | -16.69 Million |
MAP
AFFY
ROVR
CUII
WHN
MODIRUBBER